FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009686415> ?p ?o ?g. }

• W2009686415 endingPage "466" @default.
• W2009686415 startingPage "459" @default.
• W2009686415 abstract "Background Peripheral arterial disease (PAD) is a systemic inflammatory disorder that affects the entire vascular system. Endovascular therapy (EVT) is the first surgical treatment choice in a large number of patients who suffer from this disease. However, late clinical failure after primarily successful interventions, with the need of a new reintervention, is the major drawback of this technique. The aim of this study is to determine the possible association between serum high sensitivity C-reactive protein (hsCRP) and fibrinogen levels both preintervention and during follow-up, and the outcomes of EVT and their association with the incidence of cardiovascular events or death in these patients. Methods This is a prospective cohort study in patients diagnosed with PAD in the iliac, femoral, popliteal, or distal sectors, within Rutherford category 3–5 who underwent EVT de novo. We determined levels of hsCRP and fibrinogen before surgery and during the follow-up period (at 1, 3, 6, and 12 months). We analyzed the possible association among inflammatory markers levels before EVT, during 1 year of follow-up and its variation during that year, and the incidence of reintervention, reintervention-free survival, and the occurrence of cardiovascular events or death. Results Over the course of 1 year, 246 patients underwent a revascularizing treatment of the lower limbs; 64 patients qualified for inclusion in this study. In these 64 patients, a significant increase between basal hsCRP and fibrinogen levels and the incidence of reintervention (P = 0.002 and 0.013, respectively) and death (P = 0.001 and 0.013, respectively) during follow-up was found. A significant increase between higher hsCRP basal levels and the incidence of cardiovascular events during the follow-up period was also noted (P = 0.004). Levels of basal hsCRP were related to reintervention-free survival after EVT (P = 0.04). On the basis of the rate of hsCRP variation and its association with reintervention-free survival, we observed a progressive reduction of the levels of hsCRP until 12 months after the primary procedure. Conclusions Basal levels of inflammatory markers and their variation during follow-up allowed us to identify a subgroup of patients with PAD that will require a greater number of (and earlier) reinterventions after EVT and who will have higher rates of cardiovascular morbidity and mortality. Peripheral arterial disease (PAD) is a systemic inflammatory disorder that affects the entire vascular system. Endovascular therapy (EVT) is the first surgical treatment choice in a large number of patients who suffer from this disease. However, late clinical failure after primarily successful interventions, with the need of a new reintervention, is the major drawback of this technique. The aim of this study is to determine the possible association between serum high sensitivity C-reactive protein (hsCRP) and fibrinogen levels both preintervention and during follow-up, and the outcomes of EVT and their association with the incidence of cardiovascular events or death in these patients. This is a prospective cohort study in patients diagnosed with PAD in the iliac, femoral, popliteal, or distal sectors, within Rutherford category 3–5 who underwent EVT de novo. We determined levels of hsCRP and fibrinogen before surgery and during the follow-up period (at 1, 3, 6, and 12 months). We analyzed the possible association among inflammatory markers levels before EVT, during 1 year of follow-up and its variation during that year, and the incidence of reintervention, reintervention-free survival, and the occurrence of cardiovascular events or death. Over the course of 1 year, 246 patients underwent a revascularizing treatment of the lower limbs; 64 patients qualified for inclusion in this study. In these 64 patients, a significant increase between basal hsCRP and fibrinogen levels and the incidence of reintervention (P = 0.002 and 0.013, respectively) and death (P = 0.001 and 0.013, respectively) during follow-up was found. A significant increase between higher hsCRP basal levels and the incidence of cardiovascular events during the follow-up period was also noted (P = 0.004). Levels of basal hsCRP were related to reintervention-free survival after EVT (P = 0.04). On the basis of the rate of hsCRP variation and its association with reintervention-free survival, we observed a progressive reduction of the levels of hsCRP until 12 months after the primary procedure. Basal levels of inflammatory markers and their variation during follow-up allowed us to identify a subgroup of patients with PAD that will require a greater number of (and earlier) reinterventions after EVT and who will have higher rates of cardiovascular morbidity and mortality." @default.
• W2009686415 created "2016-06-24" @default.
• W2009686415 creator A5002866521 @default.
• W2009686415 creator A5008678869 @default.
• W2009686415 creator A5061093769 @default.
• W2009686415 creator A5065637009 @default.
• W2009686415 creator A5080119662 @default.
• W2009686415 creator A5088166839 @default.
• W2009686415 date "2013-05-01" @default.
• W2009686415 modified "2023-10-16" @default.
• W2009686415 title "Inflammatory Burden Predicts Long-Term Outcomes in Endovascular Therapy in Peripheral Arterial Disease" @default.
• W2009686415 cites W1976760670 @default.
• W2009686415 cites W1984076481 @default.
• W2009686415 cites W1993962985 @default.
• W2009686415 cites W2013521697 @default.
• W2009686415 cites W2039462257 @default.
• W2009686415 cites W2047782327 @default.
• W2009686415 cites W2067097428 @default.
• W2009686415 cites W2068218731 @default.
• W2009686415 cites W2100414222 @default.
• W2009686415 cites W2131979392 @default.
• W2009686415 cites W2144985796 @default.
• W2009686415 cites W2157919906 @default.
• W2009686415 cites W2163092745 @default.
• W2009686415 cites W2167266673 @default.
• W2009686415 cites W2169026080 @default.
• W2009686415 doi "https://doi.org/10.1016/j.avsg.2012.02.027" @default.
• W2009686415 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23403331" @default.
• W2009686415 hasPublicationYear "2013" @default.
• W2009686415 type Work @default.
• W2009686415 sameAs 2009686415 @default.
• W2009686415 citedByCount "19" @default.
• W2009686415 countsByYear W20096864152014 @default.
• W2009686415 countsByYear W20096864152015 @default.
• W2009686415 countsByYear W20096864152016 @default.
• W2009686415 countsByYear W20096864152019 @default.
• W2009686415 countsByYear W20096864152020 @default.
• W2009686415 countsByYear W20096864152021 @default.
• W2009686415 countsByYear W20096864152022 @default.
• W2009686415 countsByYear W20096864152023 @default.
• W2009686415 crossrefType "journal-article" @default.
• W2009686415 hasAuthorship W2009686415A5002866521 @default.
• W2009686415 hasAuthorship W2009686415A5008678869 @default.
• W2009686415 hasAuthorship W2009686415A5061093769 @default.
• W2009686415 hasAuthorship W2009686415A5065637009 @default.
• W2009686415 hasAuthorship W2009686415A5080119662 @default.
• W2009686415 hasAuthorship W2009686415A5088166839 @default.
• W2009686415 hasConcept C120665830 @default.
• W2009686415 hasConcept C121332964 @default.
• W2009686415 hasConcept C126322002 @default.
• W2009686415 hasConcept C141071460 @default.
• W2009686415 hasConcept C164705383 @default.
• W2009686415 hasConcept C188816634 @default.
• W2009686415 hasConcept C2777466421 @default.
• W2009686415 hasConcept C2779036427 @default.
• W2009686415 hasConcept C2779134260 @default.
• W2009686415 hasConcept C3018348675 @default.
• W2009686415 hasConcept C46762472 @default.
• W2009686415 hasConcept C61511704 @default.
• W2009686415 hasConcept C71924100 @default.
• W2009686415 hasConcept C72563966 @default.
• W2009686415 hasConceptScore W2009686415C120665830 @default.
• W2009686415 hasConceptScore W2009686415C121332964 @default.
• W2009686415 hasConceptScore W2009686415C126322002 @default.
• W2009686415 hasConceptScore W2009686415C141071460 @default.
• W2009686415 hasConceptScore W2009686415C164705383 @default.
• W2009686415 hasConceptScore W2009686415C188816634 @default.
• W2009686415 hasConceptScore W2009686415C2777466421 @default.
• W2009686415 hasConceptScore W2009686415C2779036427 @default.
• W2009686415 hasConceptScore W2009686415C2779134260 @default.
• W2009686415 hasConceptScore W2009686415C3018348675 @default.
• W2009686415 hasConceptScore W2009686415C46762472 @default.
• W2009686415 hasConceptScore W2009686415C61511704 @default.
• W2009686415 hasConceptScore W2009686415C71924100 @default.
• W2009686415 hasConceptScore W2009686415C72563966 @default.
• W2009686415 hasIssue "4" @default.
• W2009686415 hasLocation W20096864151 @default.
• W2009686415 hasLocation W20096864152 @default.
• W2009686415 hasOpenAccess W2009686415 @default.
• W2009686415 hasPrimaryLocation W20096864151 @default.
• W2009686415 hasRelatedWork W1781122166 @default.
• W2009686415 hasRelatedWork W1967567793 @default.
• W2009686415 hasRelatedWork W2002216275 @default.
• W2009686415 hasRelatedWork W2003127700 @default.
• W2009686415 hasRelatedWork W2143483143 @default.
• W2009686415 hasRelatedWork W2158117084 @default.
• W2009686415 hasRelatedWork W2312357239 @default.
• W2009686415 hasRelatedWork W2406760059 @default.
• W2009686415 hasRelatedWork W114799024 @default.
• W2009686415 hasRelatedWork W2521952050 @default.
• W2009686415 hasVolume "27" @default.
• W2009686415 isParatext "false" @default.
• W2009686415 isRetracted "false" @default.
• W2009686415 magId "2009686415" @default.
• W2009686415 workType "article" @default.